Anika Therapeutics (ANIK) Cash & Equivalents (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash & Equivalents data on file, last reported at $41.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 23.14% year-over-year to $41.0 million in Q1 2026; TTM through Mar 2026 was $41.0 million, a 23.14% decrease from a year earlier, with the FY2025 full-year figure at $57.5 million, up 3.33% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $41.0 million, down from $57.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ANIK reached as high as $91.4 million in Q2 2022 and fell as low as $41.0 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $67.8 million across 5 years, with a median of $65.1 million in 2023.
• Across the five-year window, Cash & Equivalents slipped 28.8% in 2023 and increased 3.33% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $86.3 million in 2022, then dropped by 20.37% to $68.7 million in 2023, then dropped by 19.07% to $55.6 million in 2024, then advanced by 3.33% to $57.5 million in 2025, then retreated by 28.64% to $41.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $41.0 million in Q1 2026, $57.5 million in Q4 2025, and $58.0 million in Q3 2025.